Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EnteroMix (EM-I-2024) in Advanced Solid Tumors
NCT07584668Phase 1Active, not recruiting
- Start
- Jul 2025
- Primary completion
- Dec 2026
- Countries
- 1
01
Overview
Phase 1, open-label trial of EnteroMix in solid tumor (2 arms). Primary endpoint: Quantitative content of the viral drug in the peripheral blood at Day 3. Started Jul 2025; status: active, not recruiting.
02
Drugs
EnteroMix
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07584668.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07584668.